Selective Engineering of the CD4 Receptor: A Host-Directed Strategy to Reduce Cellular Susceptibility to HIV Entry

Author: Amirali Ahmadi

Affiliation: National Organization for Development of Exceptional Talents (SAMPAD), Rafsanjan, Iran

Email: amiraliahmadi138861@gmail.com

Abstract

HIV infection remains incurable due to the integration of the viral genome into CD4+ T cells and the establishment of latent reservoirs, which persist despite effective antiretroviral therapy. CCR5-editing strategies, while promising, face inherent limitations including viral tropism switching to CXCR4 and genetic heterogeneity across human populations. [16, 13, 10, 6, 4]

Recent studies have directly targeted CD4 to inhibit HIV. Ahmadi et al. (2024) developed anti-CD4 nanobodies that block HIV entry by altering CD4 conformation [17]. Zhang et al. (2026) showed that HIV changes CD4+ T cell surface glycans to evade immunity [18]. Liu et al. (2026) analyzed immune recovery in HIV-treated patients [19]. These findings support engineering CD4 as a host-directed strategy, as proposed here.

Here, we propose a theoretical framework for the selective engineering of the CD4 receptor, aimed at reducing T-cell susceptibility to HIV entry through targeted structural modification. This framework is grounded in a key biophysical distinction: the high-affinity, focused binding of viral gp120 versus the lower-affinity, dynamic, and spatially extended interaction of CD4 with MHC-II. [14, 9]

We hypothesize that the insertion of a protective domain in proximity to the gp120-binding site could selectively impair viral docking while preserving CD4–MHC-II engagement within a physiologically tolerable range [1, 7, 15]. Such modification may also constrain the evolutionary adaptability of HIV more effectively than coreceptor-targeted strategies. [10, 11, 13]

This conceptual framework provides a foundation for the experimental evaluation of host receptor engineering as a complementary approach to achieving sustained cellular resistance to HIV infection.

Keywords

CRISPR-Ca HIV, CD4 receptor engineering, host-directed strategy, protein-protein interaction, gene editing, s9

1.Introduction

The persistence of HIV infection is not primarily driven by active viral replication, but by the establishment of latent reservoirs in CD4+ T cells. These reservoirs persist even in the presence of effective combination antiretroviral therapy (ART) and render complete eradication unattainable [4, 16]. Consequently, numerous emerging therapeutic strategies have shifted focus from merely suppressing viral replication toward engineering durable resistance in host cells**.**

Gene editing of the CCR5 coreceptor—inspired by rare cases of successful cure following transplantation of CCR5-Δ32 homozygous stem cells—represents a prominent example of this host-directed paradigm [6]. However, reliance on the disruption of a single auxiliary coreceptor entails intrinsic limitations, including the risk of viral tropism switching to CXCR4 and considerable genetic heterogeneity across diverse populations [10, 13]. These constraints raise a fundamental question: does targeting coreceptors, rather than the primary receptor, constitute an optimal strategy**?**

Efforts to directly disrupt the gp120–CD4 interaction have predominantly focused on small molecules and CD4-mimetic peptides [1, 7]. Although such compounds have demonstrated the capacity to reduce viral binding in vitro, their clinical translation has been hampered by limited in vivo stability and the remarkable ability of HIV to evade single-site inhibition through mutational adaptation [11]. Similarly, cell-based immunotherapies such as CAR-T are primarily designed to eliminate already infected cells rather than to prevent de novo viral entry[2,3,5].

A discernible conceptual gap thus emerges in the existing literature: the primary CD4 receptor—despite its indispensable role across all HIV-1 strains—has received comparatively little attention as a target for sustained structural engineering. Apprehension regarding potential disruption of CD4-dependent immune function has likely contributed to this restraint**.**

In this paper, we propose a theoretical framework for the selective engineering of the CD4 receptor. This framework is predicated on the fundamental biophysical distinction between the high-affinity, focused binding of viral gp120 and the lower-affinity, dynamic, and spatially extended interaction of CD4 with MHC-II [9, **1**4]. We hypothesize that this asymmetry can be exploited to design an intervention that selectively impairs viral docking while preserving CD4-dependent immune signaling within a physiologically acceptable range. This approach positions direct engineering of the primary receptor as a complementary, host-directed strategy against HIV entry**.**[Figure1]



Figure 1 – Schematic illustration of HIV entry into a CD4+ T cell

The viral envelope glycoprotein gp120 binds to the CD4 receptor on the host cell membrane (step 1). This binding induces a conformational change that exposes the co-receptor binding site (step 2), allowing interaction with CCR5 or CXCR4 (step 3). Subsequently, gp41 mediates fusion of the viral and cellular membranes (steps 4-5), leading to the release of the viral core into the cytoplasm (step 6).

Created by the author.

2.Molecular Basis of HIV Entry and Limitations of Current Strategies

2.1.Biophysics of the gp120–CD4 Interaction

HIV entry into target cells is initiated by a decisive molecular event: the binding of the viral envelope glycoprotein gp120 to the CD4 receptor on the surface of T lymphocytes. This interaction occurs primarily within the D1 domain of CD4, centered around the key residue Phe43—a region that fits into a complementary cavity in gp120, designated the "Phe43 cavity" [14]. The formation of this initial complex is not merely a passive adhesion event; it induces extensive conformational rearrangements in gp120 that enable subsequent engagement of secondary coreceptors, principally CCR5 or CXCR4[4].

From a biophysical standpoint, the gp120–CD4 interaction is characterized by high spatial focality, stringent dependence on precise amino acid configuration at the binding interface, and nanomolar affinity. In contrast, the physiological engagement of CD4 with MHC-II molecules during antigen presentation is spatially diffuse, dynamic, and characterized by substantially

lower (micromolar) affinity, organized within the multi-molecular architecture of the immunological synapse[14,9].

This fundamental disparity in binding geometry, affinity, and dynamics constitutes a distinct biophysical asymmetry. It raises the central question driving this study: can this asymmetry be exploited to design a selective intervention that impairs viral docking while preserving the physiological functions of CD4?

2.2.Limitations of Viral Replication Inhibition and Coreceptor Disruption

Combination antiretroviral therapy (ART) effectively suppresses active HIV replication and has dramatically increased life expectancy among people living with HIV. However, this strategy targets the viral replication cycle and exerts no effect on the latent reservoir harbored within long-lived CD4+ T cells [4, 16]. The requirement for lifelong adherence, the risk of emerging drug resistance, and substantial economic burden collectively indicate that suppression of replication is not synonymous with eradication.

Genetic disruption of the CCR5 coreceptor, inspired by the rare curative outcomes following transplantation of CCR5-Δ32 homozygous stem cells, emerged as a prominent host-directed strategy [6]. Despite considerable technical advances in CRISPR-Cas9-mediated CCR5 ablation [12], this approach is constrained by two inherent limitations:

First, viral tropism plasticity: HIV can, under selective pressure, shift its coreceptor usage to CXCR4 [10]. Second, population genetic heterogeneity: allelic variation in CCR5 across different populations limits the universal applicability of this strategy [13]. Furthermore, the physiological role of CCR5 in immune responses raises unresolved questions regarding the long-term safety of its permanent disruption.

2.3.Direct Inhibition of gp120–CD4 Binding: Progress and Obstacles

Efforts to directly block the gp120–CD4 interaction have predominantly focused on small molecules and CD4-mimetic peptides. Compounds such as HbAHP-25 and other aromatic small molecules have demonstrated the capacity to reduce viral binding in vitro[1,7].

However, the efficacy of these agents within the complex physiological environment of the human host has been constrained by limited in vivo stability due to proteolytic degradation, insufficient penetration into lymphoid tissues serving as major viral reservoirs, and the high mutational capacity of HIV, enabling escape via single point mutations within the gp120 binding interface[11]

In essence, soluble inhibitors—although conceptually attractive—remain vulnerable to HIV's evolutionary dynamics and require sustained, high-dose administration.

2.4.Elimination of Infected Cells versus Prevention of Entry

Cellular immunotherapies employing chimeric antigen receptor (CAR)-T cells adopt a fundamentally different strategy: the elimination of productively infected cells rather than prevention of de novo viral entry [2, 5]. While this approach has shown promise in preclinical models, several obstacles hinder its widespread application: limited persistence of infused CAR-T cells in vivo, high manufacturing costs under Good Manufacturing Practice (GMP) conditions, and risk of selecting escape variants that downregulate or mutate the target epitope[3].

Critically, these strategies operate post-entry and do not prevent the initial infection of susceptible target cells.

2.5.A Conceptual Gap: Direct Engineering of the Primary Receptor

A review of existing strategies reveals a predominant focus on three distinct axes: (1) suppression of viral replication, (2) disruption of auxiliary coreceptors, and (3) elimination of infected cells. Within this landscape, the primary CD4 receptor—an absolute requirement for entry across all HIV-1 strains—has received surprisingly limited attention as a target for sustained structural engineering.

Apprehension regarding potential compromise of CD4-dependent immune function has likely contributed to this restraint. However, the marked differences in the structural and dynamic features of gp120 binding versus physiological CD4–MHC-II interaction suggest that this receptor is not inherently "untouchable"[14,9].

This observation forms the conceptual foundation of the present study and frames its central hypothesis: Can CD4 be engineered to attenuate viral entry while preserving its essential role in immune signaling?

The following section delineates a theoretical framework constructed to address this question.

3.Conceptual Framework for Selective Engineering of the CD4 Receptor

3.1.Structural and Functional Asymmetry in CD4-Mediated Interactions

The CD4 receptor is a central component of adaptive immune regulation. Through its engagement with MHC-II molecules within the immunological synapse, CD4 facilitates the activation and sustained signaling of helper T lymphocytes. This physiological interaction is multipoint, dynamic, and dependent on the spatial organization of a larger assembly comprising co-stimulatory molecules and the TCR complex. Within this framework, CD4 function emerges not from a single contact point, but from a coordinated, supramolecular architecture[9].

In stark contrast, HIV entry is dependent upon a spatially focused, high-affinity interaction between gp120 and a confined region within the D1 domain of CD4, centered on the critical Phe43 residue. This residue fits into a complementary hydrophobic cavity in gp120—the

"Phe43 cavity"—and this engagement induces the conformational rearrangements required for exposure or stabilization of the coreceptor binding site[14].

This fundamental dichotomy between a diffuse, network-based interaction (CD4–MHC-II) and a focal, structurally constrained interaction (gp120–CD4) constitutes a distinct biophysical asymmetry. We propose that this asymmetry can be exploited to design interventions that selectively impair viral docking without fundamentally disrupting the functional architecture of the immunological synapse.

3.2.Design Rationale for Selective CD4 Engineering

Our proposed framework is predicated on a central hypothesis: the gp120–CD4 interaction, owing to its focused nature and stringent dependence on precise spatial complementarity, is more vulnerable to localized structural perturbations than the diffuse, dynamic CD4–MHC-II interaction[14,9].

Accordingly, the introduction of limited modifications in proximity to the gp120-binding site—including controlled steric occlusion, subtle modulation of D1 domain conformational dynamics, or localized remodeling of surface physicochemical properties—may be sufficient to significantly impair viral binding efficiency.

Because gp120 binding requires precise access to the Phe43 cavity and triggers obligate, ordered conformational transitions within the gp120–gp41 complex, even minor alterations in the local geometry or mechanical rigidity of this region may reduce the probability of forming a stable, functional entry complex. Conversely, the CD4–MHC-II interaction, supported by broader contact surfaces and stabilized by lateral clustering within the immunological synapse, may exhibit greater functional resilience to spatially restricted modifications [9].

Within this framework, CD4 engineering is conceptualized as selective structural reprogramming—neither wholesale receptor ablation nor complete functional inhibition. The objective is to attenuate cellular susceptibility to HIV at the entry level while preserving a physiologically tolerable threshold of CD4-dependent immune signaling.[figure2]



Figure 2 – Mechanistic model of mechanoselective CD4 engineering.

(step 1) Native HIV entry pathway. High-affinity binding of gp120 to the CD4 receptor (Phe43 cavity) triggers co-receptor engagement (CCR5 or CXCR4) and subsequent membrane fusion.

(step 2) Engineered CD4–PD (protective domain). The protective domain is inserted near the gp120-binding interface, creating steric hindrance that blocks stable viral docking and prevents entry.

(step 3) Preserved immune function. CD4-PD retains the ability to engage MHC-II molecules within the immunological synapse through weak, distributed forces, allowing normal T-cell receptor (TCR) signaling.

Created by the author.

3.3. Predicted Functional and Evolutionary Implications

If successfully realized, this strategy could establish intrinsic cellular resistance to HIV entry—a barrier that operates prior to the initiation of the viral replication cycle. Unlike ART, which targets post-entry replication events, or CCR5-directed strategies, which focus on auxiliary coreceptor pathways, CD4 engineering directly targets the obligate, non-redundant initial recognition step of the primary receptor.

From an evolutionary perspective, the invariant dependence of HIV on CD4 engagement represents a functional bottleneck in the viral life cycle. Although HIV possesses considerable mutational and adaptive capacity, extensive structural remodeling of the gp120 binding interface required to fully evade an engineered CD4 receptor may incur significant fitness costs, including reduced structural stability or diminished entry efficiency [11]. Thus, the

evolutionary landscape accessible to the virus in this region is likely more constrained than that associated with coreceptor adaptation. However, definitive exclusion of viral escape requires empirical investigation.

Furthermore, by preserving—rather than abrogating—CD4-dependent immune function, this approach may mitigate the risks of broad immunosuppression or global functional deficits associated with complete receptor knockout.

3.4.Conceptual Differentiation from Existing Strategies

Current therapeutic paradigms can be broadly categorized into three mechanistic axes: suppression of viral replication (ART), elimination of infected cells (CAR-T), and coreceptor disruption (CCR5 editing).

In contrast, direct CD4 engineering proposes a host-directed intervention at the level of the obligate, non-redundant primary receptor. Rather than targeting variable viral determinants or eliminating auxiliary immune components, this framework seeks to reprogram the fundamental structural dependency of the virus on its essential host receptor.

From this perspective, selective CD4 engineering can be defined as a structural re-tuning strategy—an approach aimed at modulating the physical parameters of the host–virus interaction, rather than merely mitigating the consequences of established infection.

Although this strategy necessitates rigorous structural, functional, and immunological validation in appropriate experimental models, it provides a conceptual foundation for the development of durable, host-directed therapeutic platforms against HIV.

4.Conceptual Feasibility and Translational Pathways for Selective CD4 Engineering

4.1.Rationale for Direct CD4 Targeting versus Coreceptor Disruption

Strategies based on inhibition or ablation of the CCR5 coreceptor have demonstrated that host genetic modification can reduce cellular susceptibility to HIV. However, viral tropism plasticity and the capacity to utilize alternative coreceptors—particularly CXCR4—constitute an inherent limitation of this approach[13,10].

In contrast, primary CD4 engagement represents an obligate and non-redundant step in the entry pathway of the vast majority of HIV-1 strains [14]. Thus, intervention at the level of the primary receptor could, in principle, impose a broader structural bottleneck against infection.

Accordingly, direct CD4 engineering is proposed as a host-directed strategy aimed at attenuating gp120 binding efficiency without completely abolishing the physiological function of the receptor. This approach is conceptually distinct from extrinsic inhibition strategies (e.g.,

CD4-mimetic molecules), which are contingent upon continuous presence of the inhibitory agent and remain vulnerable to viral escape mutations [11,7,1]

4.2.Design of a Localized Structural Modification at the gp120-Binding Site

Structural analyses derived from X-ray crystallography and cryo-electron microscopy (cryo-EM) have definitively established that gp120–CD4 engagement is critically dependent on a highly confined region within the D1 domain, particularly centered on the Phe43 residue [14]. This interaction involves precise docking into a complementary hydrophobic cavity in gp120 and induces obligate, ordered conformational transitions within the viral envelope glycoprotein complex**.**

Within our proposed framework, we hypothesize that introducing a restricted structural modification in proximity to this region—via insertion of a short peptidic sequence, introduction of controlled steric occlusion, or localized remodeling of surface electrostatic properties—may impair access to the Phe43 cavity or disrupt the conformational dynamics required for stable complex formation[15]**.**

Such a modification must satisfy three fundamental criteria. First, it must not disrupt the global folding of the CD4 molecule. Second, it must preserve proper cell-surface trafficking and expression. Third, it must not adversely affect the structural stability of adjacent domains. Consequently, rational design of this modification necessitates high-resolution structural modeling, molecular dynamics simulations, and quantitative assessment of changes in binding free energy (ΔG) relative to wild-type CD4[15]**.**

4.3.Biophysical Basis of Selectivity

The gp120–CD4 interaction is characterized by nanomolar (nM) affinity, reflecting an exceptionally stable and high-strength binding event [14]. In contrast, the physiological engagement of CD4 with MHC-II exhibits substantially lower (micromolar, μM) affinity and is reversible, dynamic, and dependent on the supramolecular organization of the immunological synapse[9]**.**

This quantitative disparity in binding affinity and kinetics is a direct consequence of the greater dependence of the viral interaction on precise spatial complementarity and complete occupancy of a confined binding pocket. Conversely, the physiological interaction—by virtue of its diffuse, multipoint nature—may exhibit greater functional resilience to spatially restricted modifications**.**

Accordingly, targeted structural alteration of the gp120-binding interface may significantly impair viral docking, while CD4–MHC-II engagement—even if partially compromised—may remain within the threshold required for productive immune signaling. This hypothesis, however, requires direct empirical validation through biophysical binding assays, lymphocyte activation studies, and quantitative assessment of downstream signaling pathways.[figure3]



Figure 3 – Mechanistic analysis of engineered CD4 receptor interactions.

(step 1) Schematic binding curves.

Native CD4 (blue curve) binds gp120 with high affinity (effective concentration <0.1 nM). The engineered CD4-PD (red curve) shows markedly reduced affinity (approximately 100 nM). This rightward shift indicates that the protective domain interferes with stable gp120-CD4 complex formation.

(step 2) Hypothetical energy barrier diagrams.

Native CD4 presents a low activation energy barrier (left), allowing gp120 to engage the receptor and proceed toward membrane fusion. In contrast, CD4-PD (right) introduces a steric obstacle that raises the energy barrier, preventing the virus from reaching the transition state required for entry.

(step 3) Preserved immune signaling.

Interaction of CD4-PD with MHC-II within the immunological synapse relies on weak, distributed forces (low affinity, multivalent contacts). These forces remain below the "threshold" required to trigger viral entry but are sufficient for normal T-cell receptor (TCR) signaling and downstream calcium flux.

Created by the author.

4.4.Potential Translational Pathways for Genetic Editing

One feasible route toward experimental implementation of this framework involves precision genome editing technologies, specifically CRISPR-Cas9-mediated homology-directed repair (HDR), in hematopoietic stem cells (HSCs)[12].

The proposed translational pipeline proceeds as follows. Autologous HSCs are first isolated from the patient. The coding sequence encoding the desired structural modification is then inserted precisely into the CD4 genomic locus. Rigorous validation of editing fidelity and exclusion of off-target modifications are performed using deep sequencing. Finally, the edited stem cells are reinfused into the patient.

If successful, this approach could generate a stable, self-renewing population of engineered immune cells constitutively expressing the modified CD4 receptor. Several critical considerations, however, warrant rigorous investigation. These include the low efficiency of HDR in primary human HSCs, the risk of off-target mutations with potentially oncogenic consequences, adverse effects on lymphoid differentiation and immune homeostasis, and the long-term immunological consequences of constitutive CD4 modification[12].[figure4]



Figure 4 – Gene editing of CD4 in hematopoietic stem cells (HSCs).

(step 1) CRISPR-Cas9 is used to insert a protective domain (PD) into the CD4 genomic locus of isolated HSCs.

(step 2) Successful insertion is verified (e.g., by sequencing).

(step 3) Edited HSCs are expanded ex vivo to obtain a sufficient cell population.

(step 4) Differentiated CD4+ T cells derived from these HSCs express the modified CD4 receptor and become resistant to gp120 binding, thereby blocking HIV entry.

Created by the author.

4.5.Theoretical Advantages and Limitations

From a theoretical perspective, direct CD4 targeting offers several potential advantages. It may substantially reduce the risk of coreceptor-mediated tropism switching, as the virus remains dependent on primary receptor engagement for entry [10, 13]. Stem cell-level editing, if achieved, could confer durable and self-renewing resistance. Furthermore, because CD4 is required by all HIV-1 strains, this approach may provide broader strain coverage than coreceptor-targeted strategies. Finally, it operates independently of extrinsic inhibitory agents, eliminating the need for chronic drug administration.

This approach, however, is accompanied by significant potential limitations. These include the risk of impairing physiological CD4 function and consequent reductions in lymphocyte activation efficiency, possible effects on thymic selection and central tolerance, the potential for viral adaptation through mutations in gp120 that circumvent the engineered structural barrier [11], and the substantial technical complexity and cost associated with genome editing under Good Manufacturing Practice conditions. Additionally, unlike pharmacologic interventions, permanent genetic modification is inherently irreversible.

4.6.Summary: A Testable Hypothesis

Selective CD4 engineering must be regarded as a conceptual framework and a testable hypothesis, not as a validated therapeutic modality. The ultimate value of this approach will be determined not by its theoretical appeal, but by its capacity to withstand rigorous, reproducible empirical evaluation.

Comprehensive structural, functional, immunological, and evolutionary validation in appropriate preclinical models constitutes an essential prerequisite for any future clinical translation. Nevertheless, the robust biophysical rationale underpinning this framework—together with the discernible conceptual gap it addresses within the existing literature—positions it as a compelling candidate for prioritized investigation.

5.Positioning of Selective CD4 Engineering Among Existing Paradigms

5.1.Comparison with Combination Antiretroviral Therapy

Combination antiretroviral therapy, by targeting key viral enzymes including reverse transcriptase, integrase, and protease, has successfully suppressed HIV replication and extended life expectancy among people living with HIV to near-population levels [4]. Despite this remarkable achievement, ART remains inherently suppressive rather than curative; it does not eliminate the latent viral reservoir [16]. Its sustained efficacy is therefore contingent upon lifelong adherence, and this requirement is accompanied by cumulative toxicity, substantial long-term economic burden, and the persistent risk of emerging drug resistance. A head-to-head comparison of the proposed framework with existing strategies is summarized in Table 1.

Strategy	Target	Mechanism	Advantages	Limitations	Ref
ART	Viral enzymes (RT, integrase, protease)	Inhibition of viral replication	Highly effective, widely available	Lifelong adherence, toxicity, latent reservoir not eliminated	[4,16]
CCR5 editing	Co-receptor CCR5	Disruption of CCR5 gene	Curative potential (Δ32/Δ32), proof-of-concept	Viral tropism switch to CXCR4, genetic heterogeneity	[6,10,12,13]
gp120-CD4 inhibitors	Viral gp120 or CD4 binding site	Small molecules or peptides	Direct blockade of entry	Poor in vivo stability, viral escape mutations	[1,7,11]
CAR-T cells	HIV-infected cells	Elimination of infected cells	Reduces viral reservoir	Post-entry, high cost, persistence issues	[2,3,5]
Selective CD4 engineering (This work)	Primary CD4 receptor	Structural modification (protective domain) near Phe43 cavity	Host-directed, blocks initial entry, preserves immune function, durable through HSC editing	Conceptual stage, off-target risks, immune complexity	—

Table 1 – Comparison of selective CD4 engineering with existing HIV therapeutic strategies

In contrast, genetic engineering of the CD4 receptor at the level of hematopoietic stem cells could, if successfully realized, establish intrinsic cellular resistance to viral entry and reduce dependence on continuous enzymatic inhibition. It must be acknowledged, however, that this approach remains at a conceptual stage and is associated with considerable technical and safety complexities that preclude direct comparison with ART in terms of clinical readiness. Accordingly, this framework is best viewed as a potential complement to—rather than an immediate replacement for—current antiretroviral regimens.

5.2.Comparison with CCR5 Engineering Strategies

The rare but definitive curative outcomes observed in patients who received stem cell transplants homozygous for the CCR5-Δ32 mutation provided compelling proof-of-concept that host genetic modification can confer sustained viral control [6]. Strategies aimed at CRISPR-mediated CCR5 ablation are predicated on this same rationale [12]. Nevertheless, this approach is constrained by a fundamental biological limitation: the capacity of HIV to engage alternative coreceptors, particularly CXCR4, under selective pressure[13,10].

By contrast, targeting CD4 is directed at the initial and obligate step of viral attachment. Since the vast majority of HIV-1 strains remain dependent on CD4 for entry [14], intervention at this level could theoretically provide broader strain coverage. This potential advantage, however, must be weighed against the greater functional risk associated with manipulating CD4—a molecule central to adaptive immune regulation—compared to the disruption of an auxiliary coreceptor. Thus, the prospective benefit of expanded viral coverage is counterbalanced by heightened immunological complexity and risk.

5.3.Comparison with gp120–CD4 Binding Inhibitors

Peptides and small molecules designed to disrupt the gp120–CD4 interaction have demonstrated capacity to reduce viral binding in vitro [1, 7]. Their translation to widespread clinical application, however, has been impeded by several recurrent obstacles: unfavorable pharmacokinetic properties, limited in vivo stability, and insufficient penetration into anatomical reservoirs of infection [11]. Moreover, the dependence of these approaches on the continuous presence of an inhibitory agent renders them particularly vulnerable to viral escape through single point mutations within the gp120 binding interface.

Within the CD4 engineering framework, the structural modification is permanently encoded within the host cell genome and therefore does not require repeated administration of an extrinsic inhibitor. This permanence, however, constitutes a double-edged sword. Unlike a pharmacologic agent whose administration can be adjusted or discontinued, permanent genetic modification is inherently irreversible and offers limited recourse in the event of unanticipated adverse effects.

5.4.Comparison with CAR-T Cell Immunotherapy

Chimeric antigen receptor T cells engineered to target HIV-infected cells are designed to recognize and eliminate productively infected cells, an approach fundamentally distinct from preventing initial viral entry [2, 3, 5]. Although this strategy has shown promise in preclinical models, several challenges have hindered its broader application: limited persistence of infused cells, high manufacturing costs under GMP conditions, and the risk of cytokine release syndrome[3].

In contrast, CD4 engineering at the hematopoietic stem cell level could, if successful, generate a self-renewing source of immune cells intrinsically resistant to viral entry. The conceptual distinction is critical: whereas CAR-T therapies operate post-entry to eliminate already infected

cells, CD4 engineering aims to reduce the probability of de novo infection. These two strategies are therefore mechanistically complementary rather than mutually competitive.

5.5.Conceptual Differentiation Based on Biophysical Binding Properties

The gp120–CD4 interaction is characterized by nanomolar affinity, reflecting an exceptionally stable and high-strength binding event [14]. By contrast, the physiological engagement of CD4 with MHC-II exhibits substantially lower—micromolar—affinity and is reversible, dynamic, and dependent on the supramolecular organization of the immunological synapse [9]. This quantitative disparity indicates that the viral interaction is more critically dependent on precise spatial complementarity and complete occupancy of a confined binding pocket than is the case for the physiological ligand.

On this basis, localized structural modification in proximity to the gp120-binding interface may significantly impair viral docking while permitting CD4–MHC-II engagement—even if partially compromised—to remain within the functional threshold required for productive immune signaling. This hypothesis, however, requires rigorous empirical validation in appropriate cellular and animal models.

5.6.Limitations and Biological Considerations

Direct manipulation of CD4 entails substantial biological challenges that must be addressed before any translational pathway can be contemplated. These include the potential impairment of T lymphocyte activation and consequent alterations in the magnitude or quality of immune responses; possible effects on thymic selection and the establishment of a competent T cell receptor repertoire; the risk of disrupting immune homeostasis or precipitating autoimmune phenomena; the capacity of HIV to adapt through structural alterations in gp120 that circumvent the engineered modification [11]; and the broader safety and ethical considerations inherent to permanent genome editing in human hematopoietic stem cells[12].

Selective CD4 engineering must therefore be regarded as a hypothesis-driven framework requiring rigorous, multi-stage validation. Comprehensive structural, functional, immunological, and evolutionary assessment in appropriate preclinical models constitutes an indispensable prerequisite for any future consideration of clinical translation.

6.Preclinical Validation Framework and Translational Pathway

Translating the conceptual framework of selective CD4 engineering into a viable therapeutic strategy necessitates rigorous, multi-level experimental validation across structural, cellular, and organismal scales. Because this approach entails direct modification of a molecule central to adaptive immune regulation, the design of preclinical studies must simultaneously pursue

two distinct objectives: first, demonstrating effective inhibition of HIV entry, and second, preserving the physiological immune-signaling functions of CD4.

6.1.Structural and Biophysical Assessment

The initial step involves validation at the level of protein structure. Molecular modeling based on molecular dynamics simulations and binding free energy calculations can be employed to predict the impact of inserting a protective domain on the overall stability of CD4 and on its interactions with both gp120 and MHC-II [15]. At this stage, quantitative analysis of parameters such as changes in binding free energy (ΔG), spatial displacement of key residues, and local conformational flexibility within the D1 domain is essential.

Following computational validation, recombinant CD4-PD variants can be produced in appropriate cell expression systems and experimentally characterized using biophysical techniques including surface plasmon resonance (SPR) or biolayer interferometry (BLI). These assays enable direct measurement of binding affinity for both gp120 and MHC-II. The objective at this stage is to demonstrate a significant reduction in gp120 binding affinity while preserving—at least partially—the CD4–MHC-II interaction.

6.2.Cellular Functional Studies

At the cellular level, it must first be established that the modified CD4 receptor is correctly folded, efficiently trafficked to the plasma membrane, and expressed at levels comparable to the wild-type protein. These assessments can be performed using flow cytometry, confocal microscopy, and analysis of surface protein half-life.

To evaluate inhibition of viral entry, pseudotyped HIV particles displaying functional gp120 provide a safe and standardized experimental system. Comparing infection rates in cells expressing wild-type CD4 versus CD4-PD offers a direct measure of entry inhibition efficacy. These assays should be conducted in the presence of both CCR5 and CXCR4 coreceptors to assess the breadth of strain coverage conferred by the modification.

Concurrently, the immunological competence of CD4-PD-expressing cells must be evaluated through MHC-II-dependent activation assays. Quantification of downstream signaling molecule phosphorylation—particularly Lck and ZAP-70—together with cytokine production profiles (IL-2, IFN-γ) and antigen-driven clonal expansion, is essential to determine the extent to which physiological CD4 function is preserved[9].

6.3.Genome Editing in Hematopoietic Stem Cells

Subsequent optimization requires precise insertion of the protective domain-encoding sequence into the endogenous CD4 locus within primary human hematopoietic stem cells [12]. Key performance indicators include editing efficiency, the ratio of homology-directed repair to non-homologous end joining, and expression levels of the modified allele. Deep sequencing is

mandatory to detect off-target modifications, and long-term clonal analysis following extended culture is necessary to assess genomic stability and the absence of deleterious mutations.

It must also be demonstrated that edited stem cells retain their capacity to differentiate into diverse lymphoid lineages and do not acquire clonal growth advantages or proliferative deficits.

6.4.Humanized Animal Models

Evaluation in humanized mouse models represents a critical gateway prior to any consideration of clinical translation. Transplantation of edited hematopoietic stem cells into immunodeficient mice permits reconstitution of a functional human immune system and enables direct assessment of susceptibility to HIV infection.

In these models, several parameters require longitudinal monitoring over extended periods: plasma viral load following HIV challenge, stability of the CD4+ T cell population, the quality and durability of adaptive immune responses, and the emergence of any inflammatory or autoimmune complications.

6.5.Evolutionary Analysis and Viral Escape Potential

Given the high mutational capacity of HIV, serial viral passage experiments in the presence of CD4-PD-expressing cells are essential to evaluate the potential for structural adaptation within gp120 [11]. Determining whether the virus can circumvent the engineered steric barrier through single or accumulated point mutations constitutes a central question in assessing the long-term durability of this strategy.

6.6.Decision Criteria for Progression to Early-Phase Clinical Trials

Cautious progression toward early-phase clinical trials can be contemplated only when preclinical data collectively demonstrate four essential conditions: first, that inhibition of viral entry is both potent and durable; second, that CD4-dependent immune function is preserved within an acceptable physiological range; third, that genome editing is both precise and stable, with no evidence of deleterious off-target effects or clonal dysregulation; and fourth, that rapid viral escape is not observed under sustained selective pressure.

This comprehensive preclinical pathway underscores that selective CD4 engineering is not a single intervention but rather a gradual, evidence-dependent process. Only through such systematic, multi-layered validation can the true therapeutic potential of this conceptual framework be rigorously assessed.



Figure 5 – Flowchart of the proposed translational pathway for selective CD4 engineering.

Steps progress from structural validation (Step 1) to early-phase clinical trials (Step 6). The diamond indicates the decision point based on four preclinical criteria (see Section 6.6).

Created by the author.

7.Safety, Regulatory, and Ethical Considerations in Selective CD4 Engineering

Genetic manipulation of the CD4 receptor in hematopoietic stem cells—given the central role of this molecule in adaptive immune regulation—demands a multidimensional assessment encompassing biosafety, genomic risk, and ethical implications. Any intervention at this level must not only demonstrate efficacy in viral inhibition but also prove defensible with respect to long-term systemic safety.

7.1.Risks Associated with Genome Editing

The use of CRISPR-Cas systems to insert a protective domain within the CD4 locus carries an inherent risk of off-target cleavage [12]. Even low-frequency off-target modifications in hematopoietic stem cells may, over time, lead to the expansion of clones harboring proliferative advantages or pre-neoplastic alterations. Accordingly, the deployment of high-fidelity Cas enzymes, nickase-based editing strategies, or base editing platforms—together with comprehensive whole-genome deep sequencing for the detection of unintended modifications—constitutes a mandatory preclinical requirement.

Furthermore, insertion of exogenous sequences into the CD4 gene must be designed to avoid disruption of regulatory elements, interference with native splicing patterns, or perturbation of physiological expression levels. Even subtle alterations in CD4 surface density can have significant consequences for lymphocyte sensitivity to antigenic stimulation.

7.2.Long-Term Immunological Consequences

CD4 serves not merely as a viral entry receptor but as an essential co-receptor within the immunological synapse, where it stabilizes TCR engagement and amplifies downstream signaling [9]. Any structural modification within its extracellular domain may therefore influence the magnitude or quality of adaptive immune responses.

Critical considerations in this domain include potential shifts in the activation threshold of T lymphocytes, effects on both positive and negative selection during thymic development with consequent reshaping of the TCR repertoire, altered interactions between CD4 and co-stimulatory molecules, and the theoretical risk of precipitating autoimmune phenomena or inducing chronic, low-grade immunodeficiency. Because such consequences may manifest only after extended latency periods, the design of both animal and human studies must incorporate longitudinal follow-up spanning several years.

7.3.Clonal Stability and Immune Homeostasis

Genetic editing at the hematopoietic stem cell level can give rise to distinct clonal subpopulations. Should the modified allele confer either a selective growth advantage or a proliferative disadvantage, the natural equilibrium of hematopoiesis may be perturbed. Clonal tracking using genetic barcoding methodologies, together with longitudinal monitoring of each clone's contribution to immune system reconstitution, will therefore constitute an essential component of safety assessment[12].

Additionally, in scenarios where editing efficiency is incomplete and a mixture of wild-type and modified CD4-expressing cells coexists, the impact of such chimerism on cellular competition and overall immune dynamics must be rigorously evaluated.

7.4.Viral Adaptation Potential and Selective Pressure

Although CD4 engagement is an invariant step in HIV entry, the virus possesses remarkable evolutionary plasticity, particularly in the gp120 envelope glycoprotein. It is theoretically possible that HIV could acquire point mutations that slightly alter its binding footprint, thereby reducing steric conflict with the engineered protective domain while still maintaining sufficient affinity for the Phe43 cavity. Such adaptive mutations would need to preserve the overall structural integrity of the gp120-CD4 interface, which could impose a significant fitness cost. However, directed evolution studies or serial viral passage experiments in the presence of CD4-PD-expressing cells would be required to empirically assess this risk. Even if partial viral escape occurs, the engineered barrier might still reduce entry efficiency, potentially allowing other host immune mechanisms to control the infection. Thus, while complete resistance to viral escape cannot be guaranteed, the proposed strategy likely creates a higher evolutionary barrier compared to coreceptor-targeted approaches.

7.5.Regulatory Considerations and Legal Frameworks

Hematopoietic stem cell-based gene therapy is subject to stringent regulatory oversight across most jurisdictions. Compliance with Good Manufacturing Practice standards, rigorous quality control of cellular products, establishment of long-term traceability mechanisms, and implementation of comprehensive adverse event reporting systems are non-negotiable prerequisites for entry into clinical trials[12].

Furthermore, the design of initial phase clinical studies demands exceptional caution, particularly regarding the selection of target populations—such as patients with inadequate responses to ART or those experiencing severe drug-related toxicities—and the prospective definition of clear study discontinuation criteria in the event of unexpected adverse outcomes.

7.6.Ethical Dimensions

Somatic genome editing in hematopoietic stem cells is ethically distinct from germline modification; nevertheless, it raises several important ethical questions. These include the assessment of risk-benefit ratios in comparison with existing, effective therapies; the challenge of obtaining meaningful informed consent in the context of substantial long-term uncertainty; equitable access to what will likely be a highly expensive, technologically sophisticated intervention; and the prevention of therapeutic overreach or applications beyond established clinical indications.

Given that ART currently provides an effective and widely accessible treatment option, any proposed genetic intervention must be convincingly justified on both safety grounds and demonstrable clinical advantage[16,4].

7.7.Summary

Selective CD4 engineering can be considered a viable therapeutic strategy only if accompanied by rigorous, transparent, and multi-layered evaluation of genomic safety, immunological function, and evolutionary vulnerability. The exceptional sensitivity of this approach derives directly from its targeting of a molecule central to adaptive immune regulation. Consequently, any progression toward clinical application must be gradual, empirically grounded, and conducted under the strictest regulatory oversight.

8.Conceptual Expansion and Broader Implications for Host Receptor Engineering

Beyond its potential application in inhibiting HIV entry, the framework of selective CD4 engineering addresses a more fundamental question: can localized modification of cellular receptors attenuate their susceptibility to pathogen engagement without significantly compromising physiological function? This question resides at the intersection of structural immunology, biophysics of molecular interactions, and genome engineering.

8.1.The Concept of Selective Modulation at the Receptor Level

Many pathogens rely on high-affinity, structurally precise interactions with specific host receptors to gain cellular entry [14]. In contrast, numerous physiological receptor-ligand interactions are characterized by dynamic, multipoint engagement and dependence on higher-order membrane organization [9]. This fundamental disparity presents, in principle, an opportunity for localized structural modification that selectively impairs pathogen docking while preserving—rather than abolishing—receptor function.

Within this framework, the objective is neither wholesale receptor ablation nor complete functional inhibition, but rather selective modulation: reducing receptor sensitivity to a non-physiological interaction while maintaining acceptable responsiveness to physiological ligands. Practical realization of this goal requires detailed understanding of epitope architecture, conformational dynamics, and receptor density-dependent signaling thresholds at the membrane interface.

8.2.Potential Generalization to Other Receptor-Dependent Pathogens

Numerous viruses and bacteria exploit specific host receptors—including immunoglobulin-like receptors, integrins, and cellular adhesion molecules—for initial attachment or entry.

In cases where pathogen engagement is confined to a discrete, structurally well-defined region of the receptor, targeted modification of that same region may similarly attenuate susceptibility to infection.

The generalizability of this framework to any given receptor–pathogen system, however, is contingent upon several interrelated factors: the degree of obligate dependence of the pathogen upon that particular receptor; the evolutionary plasticity of the pathogen and its capacity for adaptive escape; the non-redundant role of the receptor in tissue homeostasis; and the feasibility of intervention without inducing broad functional compromise. Thus, selective receptor engineering must be evaluated on a case-by-case basis, grounded in detailed structural and biophysical analysis of each specific system.

8.3.Implications for Structural Immunology and Biophysics of Molecular Interactions

This approach further underscores the importance of quantitative frameworks for analyzing molecular interactions. Parameters including binding affinity, association and dissociation kinetics (kon/koff), dependence on membrane clustering, and the mechanical forces operating upon receptor-ligand complexes collectively determine the feasibility and degree of selective modification[14,9].

Integration of data derived from X-ray crystallography, cryo-EM, molecular dynamics simulations, and force spectroscopy can provide a predictive framework for identifying which interactions are most vulnerable to localized perturbation [15]. From this perspective, receptor engineering may serve as an experimental platform for testing fundamental hypotheses regarding the functional thresholds of molecular interactions.

8.4.Synergy with Emerging Genome Editing Technologies

Recent advances in precision genome editing—particularly prime editing and base editing—have enabled the introduction of point mutations or small insertions with minimal genomic disruption. Such technologies offer the potential, in future applications, to implement increasingly subtle receptor modifications that align more closely with the logic of selective modulation.

As the scope of genetic intervention expands, however, so too does the necessity for parallel development of robust regulatory frameworks and comprehensive risk assessment protocols. The expanded application of this approach must proceed in concert with elevated standards of safety validation and scientific transparency.

8.5.Theoretical Perspective

Selective CD4 engineering can be viewed as an exemplar of a broader strategic paradigm in molecular medicine: the refocusing of therapeutic intervention from direct pathogen inhibition toward the deliberate redesign of host molecules, rendering the cellular environment intrinsically less permissive to exploitation by infectious agents. This conceptual shift, while accompanied by substantial technical and ethical complexity, may open new horizons in the design of host-directed resistance strategies.

Ultimately, the value of this framework resides not in any claim of immediate clinical applicability, but in its articulation of a testable hypothesis concerning the selective tunability of receptor–pathogen interactions. Empirical validation of this hypothesis will determine the extent to which a functional equilibrium can be established between preserving physiological competence and attenuating susceptibility to infection.

9.Conclusion

This article has presented a conceptual framework for the selective engineering of the CD4 receptor, directed toward reducing the susceptibility of T cells to HIV entry. The proposed approach is predicated on the hypothesis that fundamental structural and biophysical differences between the gp120–CD4 interaction and the physiological engagement of CD4 with MHC-II may be exploited to introduce localized modifications that attenuate viral docking while preserving—rather than abolishing—baseline immune function[14,9].

In contrast to existing therapeutic paradigms—including inhibition of viral enzymes [4], CCR5 ablation [6, 12], gp120–CD4 binding inhibitors [1, 7, 11], and cellular immunotherapies [2, 3, 5]—this strategy is distinguished by its focus on the deliberate, targeted redesign of a host molecule. This shift in the locus of intervention may, in principle, circumvent certain limitations associated with viral escape through alternative entry pathways [10, 13]. It is accompanied, however, by substantial biological and immunological complexities that cannot be minimized.

Translational realization of this framework will require rigorous, multi-level structural, functional, and evolutionary validation in appropriate preclinical models. The central challenge lies in achieving and maintaining an acceptable equilibrium between effective blockade of viral entry and preservation of adaptive immune integrity. Furthermore, comprehensive assessment of genomic safety, clonal stability, and long-term immunological consequences must precede any consideration of clinical translation[12].

Emerging evidence for CD4-targeted interventions, including nanobody-mediated neutralization [17] and glycan-based immune evasion [18], further validates the potential of receptor-centric approaches against HIV.

Selective CD4 engineering is therefore best regarded as a testable hypothesis within the broader domain of host-directed resistance strategies. Its ultimate value will be determined not by its theoretical appeal, but by its capacity to withstand rigorous, reproducible empirical interrogation.

10.References

1.Madani, N., Princiotto, A. M., Schon, A., LaLonde, J. M., Feng, Y., Freire, E., & Sodroski, J. (2008). CD4-mimetic compounds sensitize HIV-1-infected cells to antibody-dependent cellular cytotoxicity. Proceedings of the National Academy of Sciences USA, 105(43), 16886–16891.

2.Brasu, N., Elia, I., & Russo, V. (2022). Evolving strategies to eliminate the CD4 T cell HIV viral reservoir via CAR T cell immunotherapy. Frontiers in Immunology, 13, 873701.

3.Davenport, A. J., Cross, R. S., Watson, K. A., Liao, Y., Shi, W., Prince, H. M., Beavis, P. A., Trapani, J. A., Kershaw, M. H., Ritchie, D. S., Darcy, P. K., & Neeson, P. J. (2020). HIV-resistant and HIV-specific CAR-modified CD4+ T cells mitigate HIV pathogenesis in vivo. Molecular Therapy, 28(9), 2026–2037.

4.Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2016). HIV infection. Nature Reviews Disease Primers, 2, 16035.

5.Leibman, R. S., Richardson, M. W., Ellebrecht, C. T., Maldini, C. R., Glover, J. A., Secreto, A. J., Kulikovskaya, I., Lacey, S. F., Akkina, S. R., Yi, Y., Shaheen, F., Wang, J., Dufort, K. A., Hoxie, J. A., Payne, A. S., June, C. H., & Riley, J. L. (2017). Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathogens, 13(10), e1006613.

6.Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müssig, A., Allers, K., Schneider, T., Hofmann, J., Kücherer, C., Blau, O., Blau, I. W., Hofmann, W. K., & Thiel, E. (2009). Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. New England Journal of Medicine, 360(7), 692–698.

7.Schön, A., Madani, N., Klein, J. C., Hubicki, A., Ng, D., Yang, X., Smith, A. B., Sodroski, J., & Freire, E. (2016). Thermodynamics of binding of a CD4-mimetic small molecule to HIV-1 gp120. Biochemistry, 55(31), 4573–4583.

8.Richard, J., Veillette, M., Brassard, N., Iyer, S. S., Roger, M., Martin, L., Pazgier, M., Schön, A., Freire, E., Routy, J. P., Smith, A. B., Park, J., Jones, D. M., Courter, J. R., Melillo, B. N.,

Kaufmann, D. E., Hahn, B. H., Permar, S. R., Haynes, B. F., Madani, N., Sodroski, J. G., & Finzi, A. (2015). CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proceedings of the National Academy of Sciences USA, 112(20), E2687–E2694.

9.Rivinoja, M., & Smyth, R. P. (2023). Structural insights into HIV-1 entry and its inhibition. Current Opinion in Structural Biology, 82, 102726.

10.Symons, J., Cameron, P. U., & Lewin, S. R. (2017). Duality of CCR5 in HIV-1 infection: Beyond a coreceptor role. Trends in Molecular Medicine, 23(10), 881–883.

11.Ozorowski, G., Pallesen, J., de Val, N., Lyumkis, D., Cottrell, C. A., Torres, J. L., Copps, J., Stanfield, R. L., Cupo, A., Pugach, P., Moore, J. P., Wilson, I. A., & Ward, A. B. (2017). Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. Nature, 547, 360–363.

12.Walker-Sperling, V. E., & Blankson, J. N. (2024). CCR5-edited CD4+ T cells in HIV cure strategies. Molecular Therapy, 32(7), 1985–1996.

13.Wang, Z., & Sun, Z. (2024). CCR5 in HIV infection: A double-edged sword. Trends in Immunology, 45(7), 523–535.

14.Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing antibody. Nature, 393, 648–659.

15.Zafar, R., Raza, A., Javed, M. R., Alnuqaydan, A. M., Alghamdi, A., Al-barry, M. A., Rahdar, A., & Sharaf, M. (2022). Design of HIV-1 neutralizing peptides targeting the CD4-binding site: An integrative computational biologics approach. Computational and Structural Biotechnology Journal, 20, 2347–2359.

16.Zheng, Y., & Siliciano, R. F. (2024). The HIV-1 reservoir and therapeutic strategies toward eradication. Nature Reviews Microbiology, 22, 603–616.

17 .Ahmadi, M., et al. (2024). Highly potent anti-CD4 nanobodies inhibit HIV-1 by inducing CD4 conformational change. Nature Communications, 15, 6720.

18 .Zhang, Y., et al. (2026). HIV-induced sialoglycans on CD4+ T cells promote immune evasion. Nature Communications, 17, 18.

19. Liu, J., et al. (2026). CD8+ T cell dysregulation despite normalized CD4+ recovery in ART-treated HIV. Frontiers in Immunology, 17, 1735779.